Results · Apr-Jun 2026
Titan Bio-Tech Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 27% to ₹59.2 crore from ₹46.5 crore in Apr-Jun 2025.
Operating profit grew 43% to ₹12.5 crore, an operating margin of 21.1% (up 2.3 points from a year ago).
Net profit grew 58% to ₹10.9 crore from ₹6.9 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +21%, net profit +61%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 59.2 | 46.5 | +27% |
| Operating profit (EBITDA) | 12.5 | 8.7 | +43% |
| Operating margin | 21.1% | 18.8% | +2.3 pts |
| Net profit | 10.9 | 6.9 | +58% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.